Title: Management of type 1 gastric neuroendocrine tumors: An 11-year retrospective single-
center study
Version: 2 Date: 22 Sep 2023
Reviewer's report:
This paper summarizes the clinical characteristics and treatment outcomes of type 1 gastric NET
patients in large-scale single center, retrospectively. However, there are a number of obligatory
things about this paper that I can't help but point out as follows;
Major revision
1. Page 4. Materials and methods "Diagnostic criteria for type 1 gastric NETs - comprehensive
analysis for diagnosis of type 1 gastric NETs."
The authors provided diagnostic criteria for type 1 gastric NETs, but it is uncertain that thy
actually evaluated with these. In fact, there were no results for portion of positive anti#PCA or
anti-IFA and serum gastrin level. I believe it is appropriate to present the results, such as serum
gastrin level, from the patients in which it was performed, even if it was not performed in all
patients.
2. Page 4. Table 1. Evaluation of gatsroscopic manifestations of type 1 gastric NETs
The authors redefined tumor recurrence as progression of level of endoscopic manifestation in
the setting of incomplete resection. I cannot find this definition for tumor recurrence, and also I
didn't agree with it. I suggested to exclude patients with incomplete resections or not receiving
resection for accurate calculations of recurrence rate.
3. Traditional chinise medicine (TCM) was understood to be SMLJ01 in reference 24.  If you
have suggested that TCM can reduce recurrence of type 1 gastric NETs, please describe the
mechanisms, duration of treatment, indications, etc of TCM, at least in discussion section.
Minor revision
1. Page 3. Introduction. "As one of the earlist center - , and rich clinical experience".
I don't think emphasizing the institution where the research was conducted is appropriate for
objective dissertation work.
2. Page 7. Results. Clinicopathological features. "the most common manifestations were
stomach distension or stomach pain (60 cases), abdominal distension or abdominal pain (45
cases)-"
It's hard to understand the semantic difference between "stomach distention or pain" and
"abdominal distension or pain".
3. If possible, the results of laboratory test, including hemoglobin and gastrin levels, should be
presented.
4. There is a lot of redundancy in the results section, such as in the table, so it's best to summarize
the most important points where possible. (Table 2-4)
5. Although this was retrospective study, the important clinicopathologic features could not be
evaluated in 15~25% of patients; number of lesions, maximum diameter of tumor. depth of
invasion, histologic grade, stage, and metastasis (Table 2). That would certainly affected the
analyses for tumor recurrence, so it is worth describing the limitation in discussion section.
Title: Management of type 1 gastric neuroendocrine tumors: An 11-year retrospective single-
center study
Version: 2 Date: 22 Sep 2023
Reviewer's report:
This paper summarizes the clinical characteristics and treatment outcomes of type 1 gastric NET
patients in large-scale single center, retrospectively. However, there are a number of obligatory
things about this paper that I can't help but point out as follows;
Major revision
1. Page 4. Materials and methods "Diagnostic criteria for type 1 gastric NETs - comprehensive
analysis for diagnosis of type 1 gastric NETs."
The authors provided diagnostic criteria for type 1 gastric NETs, but it is uncertain that thy
actually evaluated with these. In fact, there were no results for portion of positive anti#PCA or
anti-IFA and serum gastrin level. I believe it is appropriate to present the results, such as serum
gastrin level, from the patients in which it was performed, even if it was not performed in all
patients.
2. Page 4. Table 1. Evaluation of gatsroscopic manifestations of type 1 gastric NETs
The authors redefined tumor recurrence as progression of level of endoscopic manifestation in
the setting of incomplete resection. I cannot find this definition for tumor recurrence, and also I
didn't agree with it. I suggested to exclude patients with incomplete resections or not receiving
resection for accurate calculations of recurrence rate.
3. Traditional chinise medicine (TCM) was understood to be SMLJ01 in reference 24.  If you
have suggested that TCM can reduce recurrence of type 1 gastric NETs, please describe the
mechanisms, duration of treatment, indications, etc of TCM, at least in discussion section.
Minor revision
1. Page 3. Introduction. "As one of the earlist center - , and rich clinical experience".
I don't think emphasizing the institution where the research was conducted is appropriate for
objective dissertation work.
2. Page 7. Results. Clinicopathological features. "the most common manifestations were
stomach distension or stomach pain (60 cases), abdominal distension or abdominal pain (45
cases)-"
It's hard to understand the semantic difference between "stomach distention or pain" and
"abdominal distension or pain".
3. If possible, the results of laboratory test, including hemoglobin and gastrin levels, should be
presented.
4. There is a lot of redundancy in the results section, such as in the table, so it's best to summarize
the most important points where possible. (Table 2-4)
5. Although this was retrospective study, the important clinicopathologic features could not be
evaluated in 15~25% of patients; number of lesions, maximum diameter of tumor. depth of
invasion, histologic grade, stage, and metastasis (Table 2). That would certainly affected the
analyses for tumor recurrence, so it is worth describing the limitation in discussion section.
Please review this paper.
user
Title: Management of type 1 gastric neuroendocrine tumors: An 11-year retrospective single-
center study
Version: 2 Date: 22 Sep 2023
Reviewer's report:
This paper summarizes the clinical characteristics and treatment outcomes of type 1 gastric NET
patients in large-scale single center, retrospectively. However, there are a number of obligatory
things about this paper that I can't help but point out as follows;
Major revision
1. Page 4. Materials and methods "Diagnostic criteria for type 1 gastric NETs - comprehensive
analysis for diagnosis of type 1 gastric NETs."
The authors provided diagnostic criteria for type 1 gastric NETs, but it is uncertain that thy
actually evaluated with these. In fact, there were no results for portion of positive anti#PCA or
anti-IFA and serum gastrin level. I believe it is appropriate to present the results, such as serum
gastrin level, from the patients in which it was performed, even if it was not performed in all
patients.
2. Page 4. Table 1. Evaluation of gatsroscopic manifestations of type 1 gastric NETs
The authors redefined tumor recurrence as progression of level of endoscopic manifestation in
the setting of incomplete resection. I cannot find this definition for tumor recurrence, and also I
didn't agree with it. I suggested to exclude patients with incomplete resections or not receiving
resection for accurate calculations of recurrence rate.
3. Traditional chinise medicine (TCM) was understood to be SMLJ01 in reference 24.  If you
have suggested that TCM can reduce recurrence of type 1 gastric NETs, please describe the
mechanisms, duration of treatment, indications, etc of TCM, at least in discussion section.
Minor revision
1. Page 3. Introduction. "As one of the earlist center - , and rich clinical experience".
I don't think emphasizing the institution where the research was conducted is appropriate for
objective dissertation work.
2. Page 7. Results. Clinicopathological features. "the most common manifestations were
stomach distension or stomach pain (60 cases), abdominal distension or abdominal pain (45
cases)-"
It's hard to understand the semantic difference between "stomach distention or pain" and
"abdominal distension or pain".
3. If possible, the results of laboratory test, including hemoglobin and gastrin levels, should be
presented.
4. There is a lot of redundancy in the results section, such as in the table, so it's best to summarize
the most important points where possible. (Table 2-4)
5. Although this was retrospective study, the important clinicopathologic features could not be
evaluated in 15~25% of patients; number of lesions, maximum diameter of tumor. depth of
invasion, histologic grade, stage, and metastasis (Table 2). That would certainly affected the
analyses for tumor recurrence, so it is worth describing the limitation in discussion section.
assistant